Novel Catheter for Direct Gemcitabine Delivery in Pancreatic Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new catheter system that delivers gemcitabine (a chemotherapy drug) directly into pancreatic tumors. The goal is to see if this approach is safe and works better than standard intravenous chemotherapy for locally advanced pancreatic cancer that cannot be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older with histologically confirmed (biopsy-proven) locally advanced pancreatic adenocarcinoma
- Already received at least 6 months of intravenous chemotherapy with stable or locally progressive disease (no spread to distant organs)
- Cancer is not surgically removable and has no signs of metastatic disease (spread to other organs)
- Good overall health status (ECOG score 0 or 1, meaning you can carry out most daily activities)
- Acceptable blood counts and organ function (liver, kidney, bone marrow)
- Able to attend all study visits, undergo catheterization and imaging, and provide written informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called transcatheter arterial infusion, where chemotherapy drugs are delivered directly to the tumor through a thin tube in an artery. It's for people with advanced pancreatic cancer who haven't had other treatments yet.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This trial tests gemcitabine chemotherapy in people with metastatic pancreatic cancer who cannot take FOLFIRINOX. It aims to see how well gemcitabine works based on a specific tumor marker called GemCore.
This trial tests a new injectable treatment (NRT6008) given with standard chemotherapy for people whose pancreatic cancer cannot be removed by surgery. The goal is to see if it helps control the tumor better than chemo alone.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests a new targeted therapy (EDV nanocells) combined with two standard chemotherapy drugs for people with metastatic pancreatic cancer. It is for patients whose cancer has progressed after first-line FOLFIRINOX or NALIRIFOX treatment.
Hear when a new Pancreatic Cancer Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.